Regulatory

Ascelia Pharma publishes Annual Report for the financial year 2019

2020-04-06
Download

Ascelia Pharma’s Annual Report for the financial year 2019 has today been published on the company’s website http://www.ascelia.com

For further information, please contact:
Mikael Widell, Head of IR & Communications
Email: mw@ascelia.com
Tel: +46 703 11 99 60

This information is such information as Ascelia Pharma is obliged to make public pursuant to the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7.00 p.m. CET on 6 April 2020.

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral and Oncoral – currently under development.

Mangoral is a novel contrast agent for MR-scans, currently in the pivotal Phase 3 clinical study SPARKLE. Mangoral is developed to improve the visualisation of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.

2020-05-20

Updated SPARKLE timelines due to Covid-19 impact

Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma”) today announced updated timelines for the completion and top line results of the pivotal Phase 3 study SPARKLE with the lead compound Mangoral, which are now expected in H2 2021 instead of H1 2021 as previously communicated. The expected addition of three to six months reflects the impact of the Covid-19 pandemic.
2020-05-13

Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE

Ascelia Pharma AB (publ) (ticker: ACE) today published its interim financial report for Q1-2020 (January – March 2020), which is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/
2020-05-06

Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2020

Today, on 6 May 2020, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority.